JOJavier Olazarán

Javier Olazarán

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Javier Olazarán has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • No hay razones científicas para jubilar al MMSE

    by J. Olazarán Rodríguez, F. Bermejo Pareja


  • Open Access

    Social robots in advanced dementia

    by Meritxell Valentí Soler, Luis Agüera-Ortiz, Javier Olazarán Rodríguez, Carolina Mendoza Rebolledo, Almudena Pérez Muñoz, Irene Rodríguez Pérez, Emma Osa Ruiz, Ana Barrios Sánchez, Vanesa Herrero Cano, Laura Carrasco Chillón, et al.

    Aims: Testing the effect of the experimental robot-based therapeutic sessions for patients with dementia in: a controlled study of parallel groups of nursing home patients comparing the effects of therapy sessions utilizing a humanoid robot (NAO), an animal-shaped robot (PARO), or a trained dog (DOG), with conventional therapy (CONTROL) on symptoms of dementia; and an experience for patients who attend a day care center, comparing symptom prevalence and severity before and after sessions utilizing NAO and PARO. Methods: In the nursing home, patients were randomly assigned by blocks, based on dementia severity, to one of the 3 therapeutic groups to compare: CONTROL, PARO and NAO (phase 1) and CONTROL, PARO and DOG (phase 2). In the day care center, all patients received therapy with NAO (phase 1) and PARO (phase 2). Therapy sessions were held 2 days/week for 3 months. Evaluation at baseline and follow-up was carried out by blind raters using: the Global Deterioration Scale (GDS), the Severe Mini Mental State Examination (sMMSE), the Mini Mental State Examination (MMSE), the Neuropsychiatric Inventory (NPI), the Apathy Scale for Institutionalized Patients with Dementia Nursing Home version (APADEM-NH), the Apathy Inventory (AI) and the Quality of Life Scale (QUALID). Statistical analysis included descriptive statistics and non parametric tests performed by a blinded investigator. Results: In the nursing home, 101 patients (phase 1) and 110 patients (phase 2) were included. There were no significant differences at baseline. The relevant changes at follow-up were: (phase 1) patients in the robot groups showed an improvement in apathy; patients in NAO group showed a decline in cognition as measured by the MMSE scores, but not the sMMSE; the robot groups showed no significant changes between them; (phase 2) QUALID scores increased in the PARO group. In the day care center, 20 patients (phase 1) and 17 patients (phase 2) were included. The main findings were: (phase 1) imp


  • Pattern of and Risk Factors for Brain Microbleeds in Neurodegenerative Dementia

    by Javier Olazarán, Ana Ramos, Inmaculada Boyano, Eva Alfayate, Meritxell Valentí, Alberto Rábano, Juan Álvarez-Linera

    A cross-sectional study was conducted to describe the prevalence, locations, and risk factors for brain microbleeds (BMBs) in neurodegenerative dementia. The database of the Alzheimer Center Reina Sofía Foundation was searched, BMBs were described, and the potential associations of BMBs were investigated using univariate statistics. A total of 148 patients (age 81.6 [standard deviation 6.7], 79.1% female) were studied. Prevalence of BMBs was 44.6%. A group of patients with unusually high (ie, ≥4) number of BMBs were identified, which displayed higher number of vascular risk factors and vascular diseases. Brain microbleeds were also associated with ischemic lesions in the basal ganglia (r = .39), clinical diagnosis of Alzheimer’s disease (AD) and cerebrovascular disease (r = .33), cortical infarction (r = .20), and antiaggregant or anticoagulant treatment duration (r = .20). Brain microbleeds are associated with vascular burden and AD diagnosis in old patients with neurodegenerative dementia. More research is warranted regarding the mechanisms and potential clinical implications of these results.


    • 1 January 2014
      • Vol. 1  (3) , 151-159

    Brain Donation by Proxy: Are There Predictors in Neurodegenerative Dementia?

    by J Olazarán, J López-Álvarez, L Agüera-Ortiz, M Valentí, M A Zea-Sevilla, B González, B León-Salas, J L Dobato, A Rábano

    To describe the frequency and predictors of brain donation by relatives in patients with neurodegenerative dementia. Database review and quantitative analysis. The Alzheimer Center Reina Sofia Foundation (ACRSF), a center devoted to the care and research of patients with neurodegenerative dementia. Patients with signed consent for participation in the ACRSF research program. A set of 38 demographic, clinical, and social variables related to patient and closest relative, which were collected by the ACRSF multidisciplinary team upon patient admission. Admission data were available for 198 patients who entered the ACRSF research program; 85 of them (42.9%) died during follow-up. Mean age (SD) at admission was 82.3 (6.8) years and 80.8% of the patients were female. Family link between patient and closest relative was spouse or partner (12.0%), son or daughter (74.9%), or other link (13.1%). Brain was obtained from 56 patients (65.9%). Consent by legal representative and patient's depressive symptoms were more frequent in the donors (p<0.05, corrected) and trend was observed for more aberrant motor symptoms in the donors (p<0.05, uncorrected). A high rate of brain donation was achieved, probably due to the unique characteristics of the ACRSF and consent for research policy. Wish of alleviating suffering, as well as general interest in dementia research, possibly exerted an influence in brain donation. More research is needed to ascertain the values, motivations, and circumstances that may lead to brain donation by proxy in neurodegenerative dementia.


  • Quality of life (QoL) in community-dwelling and institutionalized Alzheimer's disease (AD) patients

    by Beatriz León-Salas, Javier Olazarán, Isabel Cruz-Orduña, Luis Agüera-Ortiz, José Luis Dobato, Meritxell Valentí-Soler, Ruben Muñiz, Ma Teresa González-Salvador, Pablo Martínez-Martín


  • Open Access

    Cumulative Effect of Depression on Dementia Risk

    by J. Olazarán, R. Trincado, F. Bermejo-Pareja

    Objective. To analyze a potential cumulative effect of life-time depression on dementia and Alzheimers disease (AD), with control of vascular factors (VFs). Methods. This study was a subanalysis of the Neurological Disorders in Central Spain (NEDICES) study. Past and present depression, VFs, dementia status, and dementia due to AD were documented at study inception. Dementia status was also documented after three years. Four groups were created according to baseline data: never depression (nD), past depression (pD), present depression (prD), and present and past depression (prpD). Logistic regression was used. Results. Data of 1,807 subjects were investigated at baseline (mean age 74.3, 59.3% women), and 1,376 (81.6%) subjects were evaluated after three years. The prevalence of dementia at baseline was 6.7%, and dementia incidence was 6.3%. An effect of depression was observed on dementia prevalence (OR [CI 95%] 1.84 [1.013.35] for prD and 2.73 [1.086.87] for prpD), and on dementia due to AD (OR 1.98 [0.983.99] for prD and OR 3.98 [1.4810.71] for prpD) (fully adjusted models, nD as reference). Depression did not influence dementia incidence. Conclusions. Present depression and, particularly, present and past depression are associated with dementia at old age. Multiple mechanisms, including toxic effect of depression on hippocampal neurons, plausibly explain these associations.


  • Motor Effects of REAC in Advanced Alzheimer's Disease: Results From a Pilot Trial

    by Javier Olazarán, Belén González, Jorge López-Álvarez, Alessandro Castagna, Emma Osa-Ruiz, Vanesa Herrero-Cano, Luis Agüera-Ortiz, Salvatore Rinaldi, Pablo Martínez-Martín, AD Research Unit Investigators

    We conducted a pilot, randomized, controlled trial to mainly investigate the feasibility, safety, and short-term motor effects of brain stimulation with radio electric asymmetric conveyer (REAC) technology in patients with advanced Alzheimer's diseas


  • Clinical and Anatomical Correlates of Gait Dysfunction in Alzheimer's Disease

    by Javier Olazarán, Juan Antonio Hernández-Tamames, Elena Molina, Pablo García-Polo, José Luis Dobato, Juan Álvarez-Linera, Pablo Martínez-Martín, AD Research Unit Investigators

    We conducted a cross-sectional study to investigate the clinical and anatomical correlates of gait dysfunction in advanced Alzheimer's disease (AD). A comprehensive clinical protocol that included cognitive, functional, behavioral, and motor variable


  • Open Access

    Alzheimer’s Disease with Vascular Component: A Distinct Clinical Entity

    by Javier Olazarán, Eloísa Navarro, José Manuel Rojo

    Background: Longitudinal reports on the clinical features of patients with Alzheimer’s disease (AD) and concomitant cerebrovascular disease are scarce. Methods: We elaborated a working definition of AD with vascular component (ADVC), and this definition was retrospectively investigated in a cohort of patients with cognitive deterioration who were prescribed a cholinesterase inhibitor during usual practice. Results: A total of 137 patients with probable AD and 66 patients with ADVC were studied during a mean follow-up period of 2.8 years. Univariate analyses demonstrated worse functional evolution and anticipation of psychotic symptoms and agitation in the ADVC group. Conclusions: The present results are consistent with an additive model of predominantly frontal-subcortical vascular damage in AD.


  • Promoting Research in Advanced Dementia: Early Clinical Results of the Alzheimer Center Reina Sofía Foundation

    by Javier Olazarán, Luis Agüera-Ortiz, Ricardo S. Osorio, Beatriz León-Salas, José Luis Dobato, Isabel Cruz-Orduña, Belén González, Meritxell Valentí, Nuria Gil-Ruiz, Belén Frades, et al.

    The Alzheimer Center Reina Sofía Foundation (ACRSF) was envisaged to address the complex and multi-disciplinary research and care needs posed by Alzheimer's disease (AD) and other neurodegenerative dementias. Patients may be admitted at ACRSF either